investor presentation april 2018
play

Investor Presentation April 2018 NYSE American: ISR Safe Harbor - PowerPoint PPT Presentation

Investor Presentation April 2018 NYSE American: ISR Safe Harbor Statement Statements in this presentation about IsoRay's future expectations, including: the advantages of our products and their delivery systems, whether interest in and use,


  1. Investor Presentation April 2018 NYSE American: ISR

  2. Safe Harbor Statement Statements in this presentation about IsoRay's future expectations, including: the advantages of our products and their delivery systems, whether interest in and use, awareness and adoption of our products will increase or continue, whether opportunities will be available to expand the market for our products, whether changes to IsoRay's management and sales team and strategy will result in growth, whether investments in sales and marketing, production and research and development will result in growth, whether our technical assistance in the brain and gynecological applications will result in a viable commercial product for sale, whether studies and protocols will produce favorable results or lead to publications, whether peer-reviewed publications of treatment results using our products will report favorable results, whether our intellectual property will adequately protect our proprietary technologies, and all other statements in this presentation, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether additional studies are released and support the conclusions of past studies, whether ongoing patient results with our products are favorable and in line with the conclusions of clinical studies and initial patient results, patient results achieved when our products are used for the treatment of cancers and malignant diseases beyond prostate, successful completion of future research and development activities, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use our products in its various forms, continued compliance with ISO standards as audited by BSI, the success of our sales and marketing efforts, changes in reimbursement rates, changes in laws and regulations applicable to our products, and other risks detailed from time to time in IsoRay's reports filed with the SEC. Unless required to do so by law, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For more information regarding risks and uncertainties that could affect IsoRay’s results of operations or financial condition review IsoRay’s filings with the Securities and Exchange Commission (in particular, it’s most recently filed Form 10-K and Form 10-Qs). IsoRay undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This presentation shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities of IsoRay nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. 2 NYSE American: ISR

  3. Overview Isoray Medical passionately designs and develops innovative and personalized permanent implant brachytherapy products that effectively treat many forms of cancer. We believe in pioneering solutions for life beyond your cancer. Isoray’s Cesium-131 isotope, with a shorter half-life and higher energy than other commonly used radioisotopes for low dose-rate (LDR) brachytherapy, has been shown to be a highly effective cancer treatment with limited side effects and quicker recovery time and as a result, is a potentially disruptive alternative to the global radiation therapy market. Market Data Ticker (NYSE MKT) ISR Price (4/18/2018) $0.44 52 Week Range $0.38 - $0.64 Market Cap $24.0 M Average Daily Trading (3 mos) ~124,000 Common Shares Outstanding 55.0 M Cash, Cash Equivalents & CD’s * $5.7 M Trailing 12 Month Revenue** $5.69 M * As of December 31, 2017; **4/1/2017 – 3/31/2018 3 NYSE American: ISR

  4. Experienced Management Team Executing Turnaround • Director, IsoRay since 2005 before appointment as Chairman and Chief Executive Tom LaVoy Officer in early 2016. Chairman of the Board and • Over 35 years experience leading and building successful, publicly traded Chief Executive Officer businesses. • Improving operational efficiencies and increasing gross profit • Refined organizational structure • Appointed Chief Operating Officer, March 2016; previously Vice-President R&D, William A. 2010 – 2016. Cavanagh • Over 20 year career in cancer treatment technologies including research and Chief Operating Officer and development of brachytherapy for treatment of prostate cancer. Chief Scientific Officer • Guiding product development and clinical strategy and investment in clinical protocols for prostate, brain, head & neck and other cancers • Joined Isoray in March 2016. Michael L. • Over 20 years’ experience of progressive growth in sales and marketing in the Krachon medical industry, including as leader of international brachytherapy commercial Vice President, Sales and team. Marketing • Restructured sales and marketing team and helped set focused sales strategy • Relaunched website and refined marketing materials and social awareness programs 4 NYSE American: ISR

  5. Management Impact Since 2016 • Reversed Revenue Trend • 5 consecutive quarters of year-over-year revenue increases • Invested in R&D and Clinical data development • Partnered with GTMedTech to progress innovative brain cancer treatment (GammaTile) through FDA and Reimbursement approval process - 510K and reimbursement determinations expected this summer • Provided direction and focus to the commercial team • Increased share in established $100M prostate market • Targeting increasing opportunities in prostate brachytherapy • Filling leadership void in market • Multiple recent studies show brachytherapy advantage in higher risk disease • Increased Gross Profit • Manufacturing and process improvements and tight expense control • Plant automation being phased in during 2018 - 2019 5

  6. The Isoray Advantage: Cesium-131 • Product advantages • Faster delivery of treatment • Higher biological dose • Medical advantages • Significant improvement in side effect profile • Patient convenience • Faster resolution of urinary symptoms • Payer advantages • Shorter term side effects reduces doctor visits • Three Generations of Isotopes • Sole Provider of Cesium-131 isotope • Iodine 125 -1950’s with high barriers to entry • Palladium 103 - 1980’s • Significant advancement in cancer • Cesium-131 - 2004 therapy • Proprietary manufacturing process • Sole source provider in World • Safely used to treat more than 11,000 patients with long term data support 6

  7. Leveraging the Cesium-131 Strategy • Cesium-131 for prostate cancer is gaining momentum • Growing market share with more effective and experienced sales force - Targeting new customers and expansion of patient selection • Recent research publications support increasing adoption • Innovative new products and partnerships to assist clinicians with treatment delivery • Developing KOL programs for individual disease states – Brain, GYN, Head & Neck • Prostate Medical Advisory Board in place • Reviewing DRG payment structures for surgical procedures in order to establish set payment pathways • Reimbursement in place for all outpatient procedures • Reimbursement for Brain treatment anticipated Summer of 2018 • Continued process and manufacturing improvements and tight expense control to continue to deliver improved Gross Profit and operating income 7

  8. Bottom and Top Line Impact: Five Quarters of Revenue and Gross Profit Improvements Product sales, net Gross profit $ 700 $ 1,700 $ 1,600 $ 600 $ 1,500 $ 500 $ 1,400 $ 400 $ 1,300 $ 300 $ 1,200 $ 1,100 $ 200 $ 1,000 $ 100 $ 900 $ 0 $ 800 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3E Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3E 2016 2016 2016 2016 2017 2017 2017 2017 2018 2018 2018 $ (100) 2016 2016 2016 2016 2017 2017 2017 2017 2018 2018 2018 FY Quarter FY Quarter - IsoRay fiscal year ends June 30 th - Q3 2018 preliminary results were released April 18, 2018; final results will be released in early May 2018 8 NYSE American: ISR

Recommend


More recommend